Aliyeh Ranjbar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aliyeh Ranjbar has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hamid Nasrolahi
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications - Masoumeh Ghoddusi Johari
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
2 shared publications - Vahid Zangouri
Surgical Oncology Division, General Surgery Department Shiraz University of Medical Sciences Shiraz Iran
2 shared publications - Abdolrasoul Talei
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication Ali Ghaeini Hesarooeih
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication- Ali Goodarzi
Shiraz University of Medical Sciences Department of Orthopedic Surgery
1 shared publication
Latest Publications
- 16 November 2026
- Published by Wiley in Surgical Practice
Comparison of Clinicopathologic Characteristics and Survival Outcome Between Invasive Papillary Carcinoma and Invasive Ductal Carcinoma
Introduction: Invasive papillary carcinoma (IPC) of the breast is an exceptionally rare histological subtype. This study compared the clinicopathological characteristics, biomarker expression profiles and survival outcomes of IPC with those of invasive ductal carcinoma of no special type (IDC‐NST). Materials and Methods: The medical records of 6599 patients treated at the Breast Disease Research Center between December 1993 and December 2021 were retrospectively reviewed. Patients were categorized into IPC ( n = 27) and IDC ( n = 6572) groups. Tumour size, axillary lymph node status, pathologic stage, histologic grade, hormone receptor status (ER, PR), HER2 status, surgical management, adjuvant therapies and survival outcomes were analysed and compared. Survival distributions were evaluated using Kaplan–Meier curves and compared using the log‐rank test. Results: Patients with IPC were significantly older at presentation than those with IDC (mean age: 58.5 ± 14.0 vs. 49.0 ± 12.4 years, p = 0.02). Compared with IDC, IPC tumours demonstrated significantly less aggressive features, including a lower rate of axillary lymph node involvement (14.8% vs. 39.2%, p < 0.001) and a lower incidence of lymphovascular invasion (14.9% vs. 53.3%, p < 0.001). IPC tumours were predominantly low‐grade (Grade I: 70.3% vs. 20.5%, p < 0.001) and presented more frequently at Stage I (85.1% vs. 39.8%, p < 0.001). Adjuvant chemotherapy was administered significantly less often in the IPC group than in the IDC group (62.9% vs. 94.9%, p < 0.001). In stage‐specific analyses of Stage I disease, IPC exhibited favourable 5‐year disease‐free survival (81% vs. 69%, p = 0.008) and 5‐year overall survival (85% vs. 75%, p = 0.001) compared with Stage I IDC. Conclusion: IPC is a rare tumour type that presents unique clinicopathological characteristics and is associated with a higher rate of breast‐conserving surgery and a favourable prognosis than IDC.
- 16 November 2026
- Published by Wiley in Surgical Practice
Comparison of Clinicopathologic Characteristics and Survival Outcome Between Invasive Papillary Carcinoma and Invasive Ductal Carcinoma
Introduction: Invasive papillary carcinoma (IPC) of the breast is an exceptionally rare histological subtype. This study compared the clinicopathological characteristics, biomarker expression profiles and survival outcomes of IPC with those of invasive ductal carcinoma of no special type (IDC‐NST). Materials and Methods: The medical records of 6599 patients treated at the Breast Disease Research Center between December 1993 and December 2021 were retrospectively reviewed. Patients were categorized into IPC ( n = 27) and IDC ( n = 6572) groups. Tumour size, axillary lymph node status, pathologic stage, histologic grade, hormone receptor status (ER, PR), HER2 status, surgical management, adjuvant therapies and survival outcomes were analysed and compared. Survival distributions were evaluated using Kaplan–Meier curves and compared using the log‐rank test. Results: Patients with IPC were significantly older at presentation than those with IDC (mean age: 58.5 ± 14.0 vs. 49.0 ± 12.4 years, p = 0.02). Compared with IDC, IPC tumours demonstrated significantly less aggressive features, including a lower rate of axillary lymph node involvement (14.8% vs. 39.2%, p < 0.001) and a lower incidence of lymphovascular invasion (14.9% vs. 53.3%, p < 0.001). IPC tumours were predominantly low‐grade (Grade I: 70.3% vs. 20.5%, p < 0.001) and presented more frequently at Stage I (85.1% vs. 39.8%, p < 0.001). Adjuvant chemotherapy was administered significantly less often in the IPC group than in the IDC group (62.9% vs. 94.9%, p < 0.001). In stage‐specific analyses of Stage I disease, IPC exhibited favourable 5‐year disease‐free survival (81% vs. 69%, p = 0.008) and 5‐year overall survival (85% vs. 75%, p = 0.001) compared with Stage I IDC. Conclusion: IPC is a rare tumour type that presents unique clinicopathological characteristics and is associated with a higher rate of breast‐conserving surgery and a favourable prognosis than IDC.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 35-43
The effectiveness of local steroid injection for the treatment of breast-limited idiopathic granulomatous mastitis: A randomized controlled clinical trial study
Introduction: Idiopathic granulomatous mastitis (IGM) is a rare, non-specific inflammatory breast disease. There are severalcontroversies regarding its standard treatment.Aim: We aimed to evaluate the efficacy of local corticosteroid injection compared to systemic steroids and combined treatment of both in IGM patients.Methods: In this randomized controlled clinical trial study, 115 IGM patients were randomly allocated to three groups of localsteroid injection (Betamethasone, n = 37), systemic steroid treatment (Prednisolone + MTX, n = 37), or combined treatment ofboth (n = 41) for a follow-up period of 10 months. Clinical presentations and outcomes were compared between the groups.Results: The mean age of the study patients was 35.6 years. The mean time to complete remission was 3.17, 4.33, and 6.37 months, and the relapse rate during the treatment was 0%, 5.26%, and 13.33% in the injection, combined, and systemic therapy groups, respectively. There was no significant difference between the clinical response to treatment rate and the recurrence rate during the follow-up between the groups. Four patients in the combined therapy group and 3 patients in the systemic therapy group had steroid side effects, with no side effects in the injection group.Conclusions: Steroid injection therapy is more effective than combined therapy and systemic therapy in terms of remission and relapse rate during the treatment, and is as effective as systemic therapy in the clinical response to treatment rate and the recurrence rate during the follow-up period. Regarding the lack of side effects of the steroid injection therapy, this approach could be considered among the first-line treatment options.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 35-43
The effectiveness of local steroid injection for the treatment of breast-limited idiopathic granulomatous mastitis: A randomized controlled clinical trial study
Introduction: Idiopathic granulomatous mastitis (IGM) is a rare, non-specific inflammatory breast disease. There are severalcontroversies regarding its standard treatment.Aim: We aimed to evaluate the efficacy of local corticosteroid injection compared to systemic steroids and combined treatment of both in IGM patients.Methods: In this randomized controlled clinical trial study, 115 IGM patients were randomly allocated to three groups of localsteroid injection (Betamethasone, n = 37), systemic steroid treatment (Prednisolone + MTX, n = 37), or combined treatment ofboth (n = 41) for a follow-up period of 10 months. Clinical presentations and outcomes were compared between the groups.Results: The mean age of the study patients was 35.6 years. The mean time to complete remission was 3.17, 4.33, and 6.37 months, and the relapse rate during the treatment was 0%, 5.26%, and 13.33% in the injection, combined, and systemic therapy groups, respectively. There was no significant difference between the clinical response to treatment rate and the recurrence rate during the follow-up between the groups. Four patients in the combined therapy group and 3 patients in the systemic therapy group had steroid side effects, with no side effects in the injection group.Conclusions: Steroid injection therapy is more effective than combined therapy and systemic therapy in terms of remission and relapse rate during the treatment, and is as effective as systemic therapy in the clinical response to treatment rate and the recurrence rate during the follow-up period. Regarding the lack of side effects of the steroid injection therapy, this approach could be considered among the first-line treatment options.
- Open Access
- 11 January 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (2) , e1950
Outcomes and complications of intraoperative radiotherapy versus external beam radiotherapy for early breast cancer
Background: Intraoperative radiotherapy (IORT) is an alternative for external beam radiotherapy (EBRT) for early stage breast cancer (BC). Herein, we compared outcomes, postoperative and post‐radiation complications of IORT and EBRT.Methods: We conducted a cohort study to compare complications of IORT and EBRT in patients. A checklist of the complications of IORT and EBRT, was used to assess and post‐radiation complications and outcomes.Results: Overall, 264 women (121 in IORT and 143 in EBRT group) with a mean (SD) age of 55 ± 8.6 years analyzed in this study. The IORT group (quadrantectomy + SLNB + IORT) had more severe post‐operative pain compared to the EBRT group (quadrantectomy + SLNB) (OR = 1.929, 95% CI: 1.116–3.332). Other postoperative complications, including edema, erythema, seroma, hematoma, and wound complications were not significantly different between the IORT and EBRT groups.EBRT was associated with higher rates post‐radiation complications, including erythema (95.8% vs. 21.5%), skin dryness (30.8% vs. 12.4%), pruritus (26.6% vs. 17.4%), hyperpigmentation (48.3% vs. 9.9%), and telangiectasia (1.4% vs. 0.8%). Multivariate analysis showed that erythema, skin dryness and pruritus, and hyperpigmentation were more severe in the EBRT group, while breast induration was higher in the IORT group (OR = 4.109, 95% CI: 2.242–7.531). Excellent, good, and fair cosmetic outcome was seen in 11.2%, 72%, and 16.8% of the patients in the EBRT group and 29.8%, 63.6%, and 6.6% in the IORT group, respectively, suggesting that the cosmetic outcome was significantly better in the IORT group (P < .001). There wasn't statistically significant difference in recurrence‐free survival and overall survival rates between two groups of patients who received either IORT or EBRT (P = .953, P = .56).Conclusion: IORT is considered to have lower post‐radiation complications and better cosmetic outcomes in breast cancer patients. Therefore, IORT might be used as the treatment of choice in eligible patients.
- 11 January 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (2) , e1950
Open AccessOutcomes and complications of intraoperative radiotherapy versus external beam radiotherapy for early breast cancer
Background: Intraoperative radiotherapy (IORT) is an alternative for external beam radiotherapy (EBRT) for early stage breast cancer (BC). Herein, we compared outcomes, postoperative and post‐radiation complications of IORT and EBRT.Methods: We conducted a cohort study to compare complications of IORT and EBRT in patients. A checklist of the complications of IORT and EBRT, was used to assess and post‐radiation complications and outcomes.Results: Overall, 264 women (121 in IORT and 143 in EBRT group) with a mean (SD) age of 55 ± 8.6 years analyzed in this study. The IORT group (quadrantectomy + SLNB + IORT) had more severe post‐operative pain compared to the EBRT group (quadrantectomy + SLNB) (OR = 1.929, 95% CI: 1.116–3.332). Other postoperative complications, including edema, erythema, seroma, hematoma, and wound complications were not significantly different between the IORT and EBRT groups.EBRT was associated with higher rates post‐radiation complications, including erythema (95.8% vs. 21.5%), skin dryness (30.8% vs. 12.4%), pruritus (26.6% vs. 17.4%), hyperpigmentation (48.3% vs. 9.9%), and telangiectasia (1.4% vs. 0.8%). Multivariate analysis showed that erythema, skin dryness and pruritus, and hyperpigmentation were more severe in the EBRT group, while breast induration was higher in the IORT group (OR = 4.109, 95% CI: 2.242–7.531). Excellent, good, and fair cosmetic outcome was seen in 11.2%, 72%, and 16.8% of the patients in the EBRT group and 29.8%, 63.6%, and 6.6% in the IORT group, respectively, suggesting that the cosmetic outcome was significantly better in the IORT group (P < .001). There wasn't statistically significant difference in recurrence‐free survival and overall survival rates between two groups of patients who received either IORT or EBRT (P = .953, P = .56).Conclusion: IORT is considered to have lower post‐radiation complications and better cosmetic outcomes in breast cancer patients. Therefore, IORT might be used as the treatment of choice in eligible patients.
- Open Access
- 12 September 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (9) , e6323
Benign or premalignant? Idiopathic granulomatous mastitis later diagnosed as ductal carcinoma breast cancer: Case report and review of literature
Idiopathic granulomatous mastitis (IGM) is a rare benign infectious disease of the breast, commonly presenting with a unilateral breast mass. Since GM's clinical presentation and imaging can be very similar to breast cancer, diagnosing GM can be challenging. So far, various reports have demonstrated the probable correlation and co‐occurrence of granulomatous mastitis and breast cancer. This report presents a 38‐year‐old female with invasive ductal carcinoma, previously diagnosed as IGM.
- 12 September 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (9) , e6323
Open AccessBenign or premalignant? Idiopathic granulomatous mastitis later diagnosed as ductal carcinoma breast cancer: Case report and review of literature
Idiopathic granulomatous mastitis (IGM) is a rare benign infectious disease of the breast, commonly presenting with a unilateral breast mass. Since GM's clinical presentation and imaging can be very similar to breast cancer, diagnosing GM can be challenging. So far, various reports have demonstrated the probable correlation and co‐occurrence of granulomatous mastitis and breast cancer. This report presents a 38‐year‐old female with invasive ductal carcinoma, previously diagnosed as IGM.